Litt’s Drug profile for Coagulation Factor IX (Recombinant)


BreastfeedingPediatric
  • Trade Names: Alprolix (Biogen Idec); BeneFIX (Wyeth); Idelvion (CSL Behring); Ixinity; rFIX; Rixubis (Baxter)
  • Indications: Treatment and prophylaxis of bleeding in patients with hemophilia B (congenital factor IX deficiency)
  • Class: Factor IX stimulant
  • Half-life: variable e.g. 13–43 hours (Xinity); 26 hours (Rixubis); 90–93 hours (Idelvion)
  • Clinically important, potentially hazardous interactions with:
    None known

Please login to view the rest of this drug profile.

Page last updated 08/20/2025

Symbol key

Incidence - Help

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness - Help

Hospitalization possible
Life threatening
Fatal

Warnings in other populations - Help

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric